Bowen family therapy, 36, 37 Boys Don’t

Subject Index Cry (cinema), 22 BPD. See Borderline

personality
A disorder (BPD)
Aceylcholine, 166 C
ADHD. See Attention deficit hyperactivity California Psychotherapy Alliance Scales, 90
disorder (ADHD) Case writing, 192
Advil, 51
Aesop, 1, 5 261
Agency for Health Care Policy and Research, 262 SUBJECT INDEX
171
Agitation, 166 Catecholamine depletion, 166 CBSC. See
Agoraphobia, 115–117 Change-by-session curve
AIDS, 66–68 (CBSC)
Alcoholism, 36 CBT. See Cognitive behavioral therapy (CBT)
Alice’s Adventures in Wonderland Celexa, 164
(Carroll), 32 Change, client’s theory of, 19, 71–73;
Allegiance, 37, 42, 43 conversation, content, and change in, 122–
Alliance factors, 35–37 124; learning and honoring, 73–75; and
Alliance monitoring, 64–65 privileging client’s voice, 126–145; and
Alzheimer’s Disease, 39 selection of content, 124–126; in tradition,
American Association of Marriage and Family 120–126;
Therapy (AAMFT), 13, 149 trusting, 145–146
American Counseling Association (ACA), 13 Change focus: and becoming change focused,
American Healthcare Institute, 6 American 56–63; and expanding change into heroic
Journal of Psychiatry, 25 American stories, 58–63; and listening for change,
Psychiatric Association, 56–58
29, 39 Change-by-session curve (CBSC), 108–111
American Psychological Association (APA), 2, Child Outcome Rating Scale (CORS), 224
6, 7, 13, 15, 23, 24, 33, 39, Child Session Rating Scale (CSRS), 225
83, 159, 214 Chlorpromazine, 166, 167
American Psychologist, 84 Amphetamine, Cincinnati Bengals, 69
149. See also Medication Amy (client), 44, Circular causality, 187–188
45 Citalopram, 156
Antidepressant Era, The (Healy), 29 Client: accepting goals of, 68–70; as agent of
Antidepressants, 160, 164, 165, change, 34–35, 51; casting, in heroic roles,
170–175; and children, 151–152; and drug 51–55; versus clinician ratings, 152; as
research, 152–156 critic of therapy performance, 63–71;
Anxiety, 166 engagement in therapy process, 16;
Assessment, client-directed, outcomeinformed feedback, 15,
therapy, 186–192 19; Kim, 125–126; language of, 73;
Attention deficit hyperactivity disorder (ADHD), Linda, 111; Mike, 75–78; Molly, 49;
149, 156, 157, partnering with, 97–117;
159, 160 self-report, 14
Attribution creep, 27, 28 Axis II diagnosis, Client directed: becoming, 10–12, 49–80;
29 versus theory driven, 19
B Client-directed, outcome-informed therapy:
Barbara (client), 112–113 and assessment, 186–192; goals for
Beck Depression Inventory, 152 Bible, 115 therapy, 192–194; interventions of, 194–
Bill (client), 138 198; model for, 184–186
Bioamine theories, 167–169 Clients: Amy, 44; Barbara, 112–113; Bill,
Biochemical imbalance, 165–167 Biogenic 138; Bob, 126; Emma, 201–211; Jan
amine theory, 167 Biological and Mark, 182–199; Joan, 59–63;
fundamentalism, 180 Liz and Bob, 142–145; Maria, 16–18;
Biological markers, 167–169 Pat, 128–132; Robyn, 115–117; Sam,
Biomine theories, 167–169 65–68; Sarah, 69; Sean, 51; Stacy,
Bipolar disorder, 39 132–138; Steven, 113–115
Blaming the Brain (Valenstein), 169 Clinical trials, 31, 32
Bloodletting, 10 Clonidine, 148, 149. See also Medication
Bob (client), 126 Coassessment, 190, 191
Borderline personality disorder (BPD), 8, 25, Cognitive behavioral therapy (CBT), 26, 32, 41,
30, 44 44, 147
Boston Globe, 148 Common cause, 39
Boulder conference, 21 Common factors, 52; evolution and dangers of
applying, 79–80
 Competency, 13; client, 52, 53, 133; and Evaluation, 187
effectiveness, 13; orientation, 127, Evidence-based practice, 3, 7, 21; and alliance
138; versus outcome, 14 factors, 35–37; and client factors, 34–35;
Conflict avoidance pattern, 188, 189 and model or technical factors, 37–38; myth
Content, 122–124; selecting, 124–126 of, 31–47; reliability and validity of, 46–47;
Continuing education requirement, 14 as ultimate silver bullet, 38–47
Conversation, 122–124 Expectancy factors, 37
Expertise, 190
D
Deinonychus, 50 F
Depression: adolescent, 156; biogenic amine Family Counseling Office (Vestfold, Norway),
theory of, 167; genetic, 127–132; major, 39; 108
serotonin Family Therapy Magazine, 149
theory of, 168 FDA. See Federal Drug Administration (FDA)
Destigmatization, 160–164 Dexamethasone
suppression test FDA Talk Paper (FDA Press Office), 155, 162
(DST), 167 Federal Drug Administration (FDA), 150, 154,
Diagnostic and Statistical Manual of Mental 155, 162, 172
Disorders (DSM), 22, 23, 25, Federal Drug trials, 39
28, 29, 44, 118; DSM-III, 24; First-session formula task, 143 Fluoxetine
DSM-IV, 6, 9, 10, 18, 22 (Prozac), 151, 152, 155, 156.
Diagnostic classification, 21 See also Medication French
Diagnostic disorder, 23–28; and cultural bias, psychiatrists, 166
29–30; as flawed extension of medical From Placebo to Panacea (Greenberg and
model, 30; and labeling, 27–28; and Fisher), 156
reliability, 24–25; and
validity, 25–26 Dialectical behavior G
therapy Genetic depression, 127–132
(DBT), 44 Geodon, 161, 202
Diathesis-stress paradigm, 130 Disability, GlaxoSmithKline, 162 Global Assessment
paradigm of, 198 Disrupted homeostasis, Scale, 152 Goals, 192–194
169 Division of Clinical Psychology, 39 Godzilla, 49, 50
Dodo bird verdict, 32, 33, 38, 42, 43, 51
Dopamine, 166, 167
H
Dose-effect relationship, 108
Hamilton Depression Scale, 152, 174
SUBJECT INDEX 263 Harding study, 27
Harvard University, 81
“Dose-Effect Relationship in Psychotherapy” Hay Group, 3
(American Psychologist), 84 Heart and Soul of Change (Hubble, Duncan,
Drug companies, 29 and Miller), 34
Drug Enforcement Administration, 148 Helping Alliance Questionnaire II (HAQ), 90,
Drug research, four flaws of, 92
152–156 Heraclites, 56, 57
DST. See Dexamethasone suppression test Heroic stories: creating new, 56–63; expanding
(DST) change into, 58–63; listening for, 52–55
HIV, 67
E Hollywood, 82
Eating disorders, 39 Homosexuality, 29
Eclecticism, 119, 120 Effectiveness: and Human Affairs International, 32
competence, 13;
Human Affairs International study of, 32; in I
medical health provider organizations, 13; Imipramine, 168
proof of, 12; psychotherapy, 8; and IMS Health, 148, 149, 164
Treatment of Depression Collaborative India, 165
Research Project, 26 Interpretation, 185
Elavil, 152 Intervention, 194–198
Eli Lilly and Company, 154, 155 Interview, conversation versus, 122 I-
Emma (client), 201–211 Emotionally statement strategies, 195
focused therapy (EFT), 264 SUBJECT INDEX
42–44
“Emperor’s New Drugs” (Kirsch, Moore, J
Scoboria, and Nicholls), 172 Jan and Mark (clients), 182–199 Joan
Epinephrine, 166 (client), 59–63
ESPN, 70 Journal of Consulting and Clinical Psychology,
Ethical codes, 13 6

K Anxiety and Depression
Killer D’s, 35, 127
Kim (client), 125–126
L National Association of Social Workers (NASW),
Lilly. See Eli Lilly and Company Linda
(client), 111, 112
Linear causality, 187–188
Linear regression, 110. See also Simple linear
regression (SLR)
Liz and Bob (clients), 142–145
M SUBJECT INDEX 265
Magic pill, myth of, 9. See Medication Major
depressive disorder (MDD),
155, 162
Manuals, 41
Maria (client), 16–18, 27, 53–55
Massachusetts Medicaid program, 148
MDD. See Major depressive
disorder (MDD) Medicaid, 163
Medical model, 7, 8, 10; diagnostic disorder as
extension of, 30; myth of, 21–48; relational
model versus, 19; script for, 180
Medication: and antidepressants for children,
151–152; and bioamine theories, 167–169;
and biochemical imbalance, 165–167; and
demystifying magic pill, 170–173; and
destigmatization, 160–164; and ethics of
medicating children, 148–164; and
medicated nation, 164–175; overview of,
147–148; versus therapy, 173–175
Medicine and Healthcare Products Regulatory
Agency (United Kingdom; MHRA), 162
Mental disease, concept of, 21 Mental
health care benefits, 82
Mental health practice: and client-directed,
outcomeinformed therapy assessment,
186–192; future of, 3–10; medical
model applied to, 5, 6, 8; models and, 184–
186; neurology of, 179–181; and paradigm
of disability, 198–199; and pathology, 181–
182; relational model for, 19; and
responsibility, 199–200; state of, 1–3
Mental health practitioners, 1, 2; ethical
codes of, 13
Mental Research Institute (MRI), 121, 127
Merriam-Webster’s Collegiate Dictionary, 184,
195
Methylphenidate (Ritalin), 148, 149.
See also Medication Mike (client), 75–78
Models, 37–38, 184–186
Molly (client), 49, 63, 71, 79
Montana, 50
MRI. See Mental Research Institute (MRI)
MTA Cooperative Group, 157, 158, 175
Multimodal Treatment Study of
Children with ADHD (MTA Cooperative
Group), 157
Multisystemic therapy (MST), 43, 44
N Project MATCH, 89
Narcotics Anonymous (NA), 65, 67 National
Action Agenda for Children’s
Mental Health (NAACMH), 163 National
Awareness Day, 6
National Association of Rights Protection and
Advocacy, 213–214
11
National Institute of Mental Health (NIMH), 22,
25, 26, 149, 161, 173
New England Journal of Medicine,
7, 154
New Freedom Commission of Mental Health,
29
New York Times, 63 Nicotine dependence,
39
NIMH. See National Institute of Mental Health
(NIMH)
Norepinephrine, 166, 167
Norway, 93, 108, 111
O
One Flew Over the Cuckoo’s Nest
(Kesey), 181
Outcome: and future, 117–118; informed,
becoming, 12–16; prediction of, 26; from
process to, 83–85; research, and Erickson’s
observations, 11, 12; successful, versus
competent service, 19; tracking, 86–96
Outcome management, 15 Outcome
Questionnaire 45.2 (OQ),
86–88, 92, 94
Outcome Rating Scale (ORS), 87–89, 91, 110–
113, 222; in action, 94–96;
and checking for change, 102–107; and
conversation, 124; and drug research, 156;
experimental version of, for children, 224;
experimental version of, for young children,
226; incorporating, in first meeting, 99–
100; introduction of, in first meeting, 98–
99; reliability, validity, and feasibility of,
91–94
P
Paroxetine, 156, 162
Participation, client, 36, 182
Pat (client), 128–132
Pathology, 8, 29; and pathological
labels, 15; swimming in, 181–182
Paxil, 162, 164, 165
Pedophilia, 138–142
Peer ratings, 14
Personal construct theory, 120
Pharmaceutical marketing, 163–165
Pittsburgh, Pennsylvania, 174
Placebo, 151–156, 171, 172, 175
Platelet-binding assays, 168 Position,
concept of, 121
Pretreatment change, 56
Problem focus, 189
Prozac (fluoxetine), 151–155, 161, 164,
 171, 175, 181. See also Medication
Psychiatric diagnoses, myth of, 9,
23–30; and diagnostic disorder, 23–28
Psychopharmacology, 166
Psychosis, 166
Psychotherapy Bulletin, 213
Psychotropic medications, 148, 149,
160, 164. See also Medication
Psychotherapy, and medical model, 5
R from process to outcome in, 83–85; and
Randomized clinical trial (RCT), 22, 39–41, 46
RCI. See Reliable change index (RCI)
RCT. See Randomized clinical trial (RCT)
Relational bond, cementing, 64–65
Relationship factors, 35–37 Reliability, and
diagnosis, 24–25 Reliable change index
(RCI), 110, 111
Religious beliefs, 78, 115
Reserpine, 165–168
Risperdal, 148, 164
Ritalin (methylphinidate), 148, 156, 216.
See also Medication Robyn (client), 115–
117
S Utilization (Erickson), 121
Sam (client), 65–68
Sarah (client), 69, 70
Schizophrenia, 27, 28, 165–167, 201,
202, 213, 214
Science, 27
Sean (client), 51, 56
Serotonin, 167, 168
Seroxat (paroxetine), 162
Session curve, change by, 108–110, 109fig.4.2
Session Rating Scale (SRS), 89–91, 223; in
action, 94–96; and checking for change,
102–107; and conversation, 124;
experimental version of, for
266 SUBJECT INDEX
Session Rating Scale (SRS) (continued )
children, 225; experimental
version of, for young children, 227;
incorporating, 101–102;
introducing, 100–101; reliability, validity,
and feasibility of, 91–94
Session-by-session evaluation, 16 Silver-
bullet cure, myth of. See
Evidence-based practice Simple linear
regression (SLR),
110–111; in action, 111–112
SLR. See Simple linear regression (SLR)
SSRIs, 148, 151, 152, 154–156,
161, 162, 167, 168, 171. See also
Medication
Stacy (client), 132–138
Star Trek (science-fiction series), 5, 10
Steven (client), 113–115
Stimulants, 148, 149, 160; and children, 156–
160. See also Medication
T
Talk therapy approach, 7 Television, 82
The Guardian, 162
Theory, formal versus informal, 121, 122
Theory-driven practice, client-directed
versus, 19
Therapeutic alliance, 72fig.3.1 Therapeutic
relationship, 16
Therapist allegiance, 122
Therapy: consumer tips for, 219–212; client-
directed, outcome-informed therapy’s goals
for, 192–194; drugs versus, 173–175;
factors arguing for change in, 33fig.2.1;
randomized clinical trials, 41; tailoring
tasks of, 70–71
Third-party payers, 15
Treatment of Depression Collaborative
Research Project (TDCRP), 26, 32,
36, 42, 71, 72, 89
Tricyclic antidepressants, 148, 151.
See also Medication Tylenol, 51
U
University of Southern Mississippi, 213
“Using the Outcome Rating Scale with
Couples” (Anker and Duncan),
109fig.4.2
V
Validation, 65, 131
Validity, in diagnosis, 25–26 Valium, 180
Vermont hospitals, 27
W
Working Alliance Inventory (WAI), 90, 94
World Health Organization, 168 World
Series (1999), 165
World War II, 21
X
Xanax, 180
Y
Yale University, 50
Young Child Outcome Rating Scale (YCORS),
226
Young Child Session Rating Scale (YCRS), 227
Z
Zelmid (zimelidine), 167
Zoloft, 6, 7, 161, 164, 165, 170
Zyprexa, 164